FRS2 was found to inhibit MHC-mediated tumor immune antigen presentation (red frame), with HLA-A being the most significantly affected MHC molecule (R = -0.423, P < 0.001, Figure 3c). The gene discussed is FRS2; the disease is neoplasm.